A Phase II, Randomized, Controlled, Open-Label, Feasibility Trial to Evaluate if a Single or Repeated Dose of Org 36286 (Corifollitropin Alfa) Followed by a Low Daily Dose of Either hCG [human chorionic gonadotropin] or Recombinant FSH [follicle stimulating hormone] [Urofollitropin] Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility.

Trial Profile

A Phase II, Randomized, Controlled, Open-Label, Feasibility Trial to Evaluate if a Single or Repeated Dose of Org 36286 (Corifollitropin Alfa) Followed by a Low Daily Dose of Either hCG [human chorionic gonadotropin] or Recombinant FSH [follicle stimulating hormone] [Urofollitropin] Can Induce Monofollicular Growth in Women With WHO Group II Anovulatory Infertility.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Chorionic gonadotropin; Corifollitropin alfa; Urofollitropin
  • Indications Infertility
  • Focus Therapeutic Use
  • Sponsors Organon; Schering-Plough
  • Most Recent Events

    • 11 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top